Cardiol Therapeutics (CRDL) Competitors $1.08 -0.04 (-3.13%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL vs. ATAI, URGN, ORIC, MREO, BNTC, SNDL, TKNO, CKPT, ERAS, and HUMAShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Atai Life Sciences (ATAI), UroGen Pharma (URGN), ORIC Pharmaceuticals (ORIC), Mereo BioPharma Group (MREO), Benitec Biopharma (BNTC), SNDL (SNDL), Alpha Teknova (TKNO), Checkpoint Therapeutics (CKPT), Erasca (ERAS), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Atai Life Sciences UroGen Pharma ORIC Pharmaceuticals Mereo BioPharma Group Benitec Biopharma SNDL Alpha Teknova Checkpoint Therapeutics Erasca Humacyte Atai Life Sciences (NASDAQ:ATAI) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends. Does the media favor ATAI or CRDL? In the previous week, Atai Life Sciences had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 7 mentions for Atai Life Sciences and 2 mentions for Cardiol Therapeutics. Atai Life Sciences' average media sentiment score of 0.68 beat Cardiol Therapeutics' score of -1.12 indicating that Atai Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Life Sciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cardiol Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has stronger earnings and valuation, ATAI or CRDL? Cardiol Therapeutics has lower revenue, but higher earnings than Atai Life Sciences. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Atai Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtai Life Sciences$308K1,307.10-$40.22M-$0.91-2.21Cardiol TherapeuticsN/AN/A-$20.84M-$0.34-3.19 Do analysts rate ATAI or CRDL? Atai Life Sciences currently has a consensus price target of $10.50, suggesting a potential upside of 421.09%. Cardiol Therapeutics has a consensus price target of $8.40, suggesting a potential upside of 674.19%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Atai Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has more volatility and risk, ATAI or CRDL? Atai Life Sciences has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Does the MarketBeat Community favor ATAI or CRDL? Atai Life Sciences received 307 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. However, 67.44% of users gave Cardiol Therapeutics an outperform vote while only 66.67% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformAtai Life SciencesOutperform Votes33666.67% Underperform Votes16833.33% Cardiol TherapeuticsOutperform Votes2967.44% Underperform Votes1432.56% Is ATAI or CRDL more profitable? Atai Life Sciences' return on equity of -65.75% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Atai Life SciencesN/A -65.75% -52.71% Cardiol Therapeutics N/A -194.40%-129.07% Do insiders and institutionals hold more shares of ATAI or CRDL? 28.4% of Atai Life Sciences shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 31.2% of Atai Life Sciences shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryAtai Life Sciences beats Cardiol Therapeutics on 11 of the 17 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.63M$2.95B$5.41B$8.53BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-2.7831.1426.7719.96Price / SalesN/A411.10395.44121.37Price / CashN/A168.6838.2534.62Price / Book3.393.356.874.60Net Income-$20.84M-$72.17M$3.23B$248.27M7 Day Performance-2.25%6.67%5.32%2.28%1 Month Performance11.86%10.13%13.56%16.43%1 Year Performance-51.13%-26.77%17.86%8.15% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics1.6442 of 5 stars$1.09-3.1%$8.40+674.2%-48.6%$89.63MN/A-2.7820Positive NewsGap UpATAIAtai Life Sciences2.3801 of 5 stars$1.84+11.5%$10.50+470.7%+18.5%$367.62M$308,000.00-2.2780News CoverageEarnings ReportAnalyst ForecastGap DownURGNUroGen Pharma4.1335 of 5 stars$7.97+9.0%$32.86+312.3%-41.6%$367.47M$91.87M-2.53200News CoverageGap UpTrading HaltedHigh Trading VolumeORICORIC Pharmaceuticals4.4986 of 5 stars$5.14+8.7%$19.17+272.9%-37.6%$365.39MN/A-2.8280Positive NewsMREOMereo BioPharma Group1.7866 of 5 stars$2.29+2.2%$7.71+236.9%-29.4%$364.11M$1M-32.7140BNTCBenitec Biopharma2.4444 of 5 stars$13.98+2.8%$24.71+76.8%+33.0%$357.89M$80,000.00-9.2620News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionSNDLSNDL3.1393 of 5 stars$1.30-3.7%$3.63+178.8%-44.6%$354.75M$927.61M-4.19580News CoveragePositive NewsTKNOAlpha Teknova1.7799 of 5 stars$6.54-1.1%$8.50+30.0%+275.4%$349.50M$38.25M-8.84240Gap UpCKPTCheckpoint Therapeutics1.9457 of 5 stars$4.16+0.2%$4.33+4.2%+104.9%$348.46M$41,000.00-2.2610News CoveragePositive NewsERASErasca3.6538 of 5 stars$1.23-4.3%$4.57+271.7%-42.9%$348.44MN/A-1.48120HUMAHumacyte2.3442 of 5 stars$2.23-0.4%$11.71+425.3%-64.7%$345.92M$1.57M-1.66150Analyst Revision Related Companies and Tools Related Companies ATAI Alternatives URGN Alternatives ORIC Alternatives MREO Alternatives BNTC Alternatives SNDL Alternatives TKNO Alternatives CKPT Alternatives ERAS Alternatives HUMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDL) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRDL Stock Free CRDL Stock Alerts